MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 39.59

Change

+0.20 (+0.51)%

Market Cap

USD 0.02B

Volume

5.11M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B
INSM Insmed Inc

+0.15 (+0.21%)

USD 13.20B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.47 % 0.00 %

-0.01 (0%)

USD 0.65M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

-0.09 (0%)

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

+0.10 (+0%)

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

-0.16 (0%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.06 (+0%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

-0.14 (0%)

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

-0.05 (0%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 1.69 % 0.00 %

+0.13 (+0%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 1.69 % 0.00 %

N/A

USD 0.52B
FCTR 1.68 % 0.00 %

N/A

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.01 (+0%)

USD 3.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.49 (+0%)

USD 0.08B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.95 (+0%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (0%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (0%)

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

+0.37 (+0%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.20% 28% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.20% 28% F 14% F
Trailing 12 Months  
Capital Gain -58.28% 29% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.28% 29% F 15% F
Trailing 5 Years  
Capital Gain 100.46% 88% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.46% 88% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 76.37% 82% B 91% A-
Dividend Return 76.37% 82% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 194.39% 25% F 12% F
Risk Adjusted Return 39.29% 89% A- 70% C-
Market Capitalization 0.02B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector